Original investigationsDialysis therapiesEpoetin requirements predict mortality in hemodialysis patients
Section snippets
Data sources
This study used data collected and maintained by the United States Renal Data System (USRDS). This database incorporates extensive baseline and follow-up demographic and clinical data on patients with ESRD whose care is covered by the Medicare program. Patient demographic and treatment characteristics, which include date of first ESRD service, age, sex, race, underlying disease causing ESRD, date of death, and date of first kidney transplant, were obtained from the PATIENTS file in the USRDS
General patient characteristics
We identified 145,606 prevalent adult hemodialysis patients between September 1, 2000, and December 31, 2000. Of these patients, 39,795 patients did not have 4 epoetin claims, 3,564 patients reported a type of dialysis other than hemodialysis during the entry period, 1,723 patients received a transplant before the beginning of the follow-up period, and 2,279 patients died during the entry period. Of the remaining 98,245 patients, an additional 3,676 patients were excluded because of missing URR
Discussion
In this retrospective analysis based on administrative data, we examine the relation of epoetin treatment and other baseline variables, including hematocrit, to mortality in 94,569 prevalent hemodialysis patients. Our analysis indicates considerable interpatient variability in dosing requirements for a defined hematocrit level. This result confirms previous studies showing a wide range of epoetin dose necessary to reach the National Kidney Foundation-Kidney Disease Outcomes Quality Initiative
References (43)
- et al.
Anaemia of end-stage renal disease (ESRD)
Kidney Int
(1985) - et al.
The effects of higher hemoglobin levels on mortality and hospitalization in hemodialysis patients
Kidney Int
(2003) - et al.
Association of hematocrit value with cardiovascular morbidity and mortality in incident hemodialysis patients
Kidney Int
(2004) - et al.
Acute-phase response predicts erythropoietin resistance in hemodialysis and peritoneal dialysis patients
Am J Kidney Dis
(1999) - et al.
High C-reactive protein is a strong predictor of resistance to erythropoietin in hemodialysis patients
Am J Kidney Dis
(1997) - et al.
A malnutrition-inflammation score is correlated with morbidity and mortality in maintenance hemodialysis patients
Am J Kidney Dis
(2001) - et al.
How to adjust for comorbidity in survival studies in ESRD patientsA comparison of different indices
Am J Kidney Dis
(2002) - et al.
A new method of classifying prognostic comorbidity in longitudinal studiesDevelopment and validation
J Chronic Dis
(1987) - et al.
Gaining more flexibility in Cox proportional hazards regression models with cubic spline functions
Comput Methods Programs Biomed
(1997) - et al.
Erythropoietin hyporesponsivenessFrom iron deficiency to iron overload
Kidney Int Suppl
(1999)
Effect of malnutrition-inflammation complex syndrome on EPO hyporesponsiveness in maintenance hemodialysis patients
Am J Kidney Dis
Randomized, crossover study of the effect of vitamin C on EPO response in hemodialysis patients
Am J Kidney Dis
Effect of hemoglobin levels in hemodialysis patients with asymptomatic cardiomyopathy
Kidney Int
Barriers to adequate delivery of hemodialysis
Am J Kidney Dis
Trends in anemia management among US hemodialysis patients
J Am Soc Nephrol
Management of the anaemia of chronic renal failure with recombinant erythropoietin
QJM
Recombinant human erythropoietin in anemic patients with end-stage renal diseaseResults of a phase III multicenter clinical trial
Ann Intern Med
The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin
N Engl J Med
US Renal Data SystemUSRDS 2003 Annual Data Report
K/DOQI Clinical Practice Guidelines for Anemia of Chronic Kidney Disease, Update 2000
Am J Kidney Dis
Use of clinical guidelines for treatment of anemia among hemodialysis patients
Artif Organs
Cited by (232)
Erythropoiesis-stimulating agents and cardiovascular mortality: A systematic review and meta-analysis of 17 studies and 372,156 hemodialysis patients
2023, International Journal of Cardiology: Cardiovascular Risk and PreventionSelenium Associates With Response to Erythropoiesis-Stimulating Agents in Hemodialysis Patients
2022, Kidney International ReportsPooled Analysis of Roxadustat for Anemia in Patients With Kidney Failure Incident to Dialysis
2021, Kidney International ReportsTheranova versus FX80: The impact on anemia management in hemodialysis
2024, International Journal of Artificial Organs
The data reported here have been supplied by the United States Renal Data System. The interpretation and reporting of these data are the responsibility of the authors and in no way should be seen as the official policy or interpretation of the US Government.